Enliven Therapeutics Inc
Enliven Therapeutics Inc (ELVN) Covered Calls
Enliven Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 12.70%, low versus the past year. ELVN's highest covered call setup is the $65.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 36.50% out of the money with 123 days to expiration, a 36.60% return until expiration, and a 108.62% theoretical annualized return. Across the setups shown, annualized returns run from 51.57% to 108.62% at strikes between $50.00 and $90.00, with 32 to 396 days to expiration, as of Nov 16, 2026.
Read more
Running ELVN covered calls helps you generate income from Enliven Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ELVN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ELVN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ELVN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ELVN covered call is worth writing.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| 2027-03-19 | 123 | 65.00 | 36.50 | 0.05 | 4.00 | 1743.00 | 36.60 | 108.62 | -0.10 | +0.24 | 1 | 3.95 |
| 2027-01-15 | 60 | 55.00 | 15.50 | 0.55 | 4.30 | 793.00 | 16.65 | 101.30 | -1.15 | +0.34 | 17 | 3.75 |
| 2027-12-17 | 396 | 90.00 | 89.00 | 0.05 | 3.90 | 4243.00 | 89.10 | 82.13 | -0.10 | +0.18 | 2 | 3.85 |
| 2027-03-19 | 123 | 60.00 | 26.00 | 0.45 | 4.40 | 1283.00 | 26.94 | 79.95 | -0.94 | +0.30 | 5 | 3.95 |
| 2026-12-18 | 32 | 50.00 | 5.00 | 0.95 | 2.80 | 333.00 | 6.99 | 79.76 | -1.99 | +0.41 | 49 | 1.85 |
| 2027-12-17 | 396 | 85.00 | 78.50 | 0.05 | 4.10 | 3743.00 | 78.60 | 72.45 | -0.10 | +0.20 | 0 | 4.05 |
| 2027-12-17 | 396 | 80.00 | 68.00 | 1.10 | 4.40 | 3348.00 | 70.31 | 64.80 | -2.31 | +0.24 | 2 | 3.30 |
| 2027-03-19 | 123 | 55.00 | 15.50 | 1.80 | 5.40 | 918.00 | 19.28 | 57.21 | -3.78 | +0.40 | 99 | 3.60 |
| 2027-12-17 | 396 | 75.00 | 57.50 | 1.85 | 4.70 | 2923.00 | 61.38 | 56.58 | -3.88 | +0.28 | 27 | 2.85 |
| 2027-06-17 | 213 | 60.00 | 26.00 | 1.95 | 5.50 | 1433.00 | 30.09 | 51.57 | -4.09 | +0.36 | 1 | 3.55 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank12.70% Low
- Market cap (M$)3,424
- 52 weeks high-25.34%
- 52 weeks low214.82%
- Analyst recommendationStrong Buy
1.13 - Target price$73.85
58.71% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-1.70
- EPS growth next 5 years-12.26%
As of Nov 20, 2026